MBX Biosciences to Unveil Key Data from Weekly Canvuparatide Trial for Hypoparathyroidism (HP) on September 22nd
MBX Biosciences, a clinical-stage biopharmaceutical company, will host a voice call and webcast on September 22, 2025, at 8 am ET to discuss the results from the AvailTM Phase 2 trial for a potential once-weekly treatment called canvuparatide for patients with chronic hypoparathyroidism (HP).
During the call, the company will announce the topline results from this Phase 2 clinical trial. The live and archived webcast of the call and slide presentation will be available on the Investors section of the Company's website (https://mbxbio.com/). Participants can join the call by dialing 1-877-407-0779 (US) or 1-201-389-0914 (international).
The webcast link for the conference call can be accessed at [Webcast Link]. MBX Biosciences' focus is on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.
For media inquiries, please contact Katie Beach Oltsik of Inizio Evoke Comms at [email protected] or (937) 232-4889. Investor Contact for MBX Biosciences is Jim DeNike, who can be reached at [email protected].
Follow MBX Biosciences on LinkedIn for the latest updates. The company's website is located at https://mbxbio.com/.
Read also:
- Connection Between ADHD and Trauma?
- West Nile Virus detected in Kentucky for the first time; authorities advise locals to adopt safety measures
- Authorities approve the euthanasia of a young woman from Barcelona, as requested by her father, halting the legal proceedings.
- Expansion of the care network is underway
%20on%20September%2022nd){kind=link}